OR WAIT null SECS
BOSTON, June 19, 2017 – As life science companies increasingly seek to gain insights from diverse data sources to make drug development more efficient and effective, PAREXEL International Corporation, a global biopharmaceutical services provider, announced the launch of its Connected Journey™ of data-driven services. This new network, powered by PAREXEL® Analytics capabilities, combines PAREXEL’s technology and processes, to deliver critical intelligence supporting clinical development and commercialization.
PAREXEL’s Connected Journey consists of over 40 data-driven services. Its most recent, the ForeSite™ clinical trial methodology, integrates therapeutic area expertise, real-time analytics technology, and centralized oversight to predict site productivity. The solution enables sponsors to improve feasibility and site and country selection, as well as to more effectively engage and retain sites and patients.
“While drug companies have access to more data sources than ever before, they face challenges in generating and integrating meaningful insights that drive timely and actionable decisions,” said Mark A. Goldberg, MD, president and COO, PAREXEL. “Aggregating and leveraging the right data to drive value requires a broad range of services working together to generate insights across the entire drug development and commercialization spectrum. We believe PAREXEL’s global scale and broad technical expertise offer clients a uniquely integrated and comprehensive portfolio-delivered by a single provider.”
“The data resources to inform decision making are available, but to yield true value they must all be brought together,” said Xavier Flinois, president, PAREXEL Informatics. “PAREXEL’s Connected Journey moves from single solutions to the industry’s largest system of interrelated data-driven innovations. This model seamlessly connects data, technology, processes and multi-functional expertise, and is designed to foster close collaboration with all constituents.”